First Liver transplant with STEEN Solution™ performed

The first clinical liver transplant with a liver perfused with STEEN Solution™
was performed in Toronto, Canada. In total three successful liver transplants
have been performed  as part of a phase 1 clinical trial at Toronto General
Hospital (TGH)/University Health Network.
In total three successful liver transplants were performed during the summer in
Toronto, Canada. The liver was perfused with STEEN Solution™ under normothermic
conditions. STEEN Solution™ was originally developed for warm perfusion and
evaluation of lungs and is modified when perfusing a liver. The modified STEEN
Solution™ decreases inflammation and protects the liver from injury.

“This technique will change the landscape of organ donation by improving organ
preservation, allowing us to assess or ‘test drive’ the liver on the device
before we transplant it into a patient. We will know how healthy that organ is
before the transplant operation,” says Dr. Markus Selzner, a transplant surgeon
in the Multi-Organ Transplant Program at TGH, co-investigator of the clinical
trial and the transplant surgeon who performed the donor operation. After the
Phase 1 safety trial they will move into subsequent phases examining efficacy.

XVIVO Perfusion’s product STEEN Solution™ (together with the XPS™) is the only
FDA approved device for evaluating an organ and is currently approved in the USA
for evaluation of marginal lungs prior to lung transplantation.

“With STEEN Solution™ having a proven clinical use in lungs, XVIVO perfusion is
determined to investigate the clinical use of STEEN Solution™ in other organs as
well as other areas of use such as cancer treatment. It is encouraging that the
STEEN Solution™ liver study has started,” says Magnus Nilsson, CEO XVIVO
Perfusion.

August 6, 2015
Gothenburg
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +46 31 788 21 59,
christoffer.rosenblad@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the
company’s website, www.xvivoperfusion.com

The information was submitted for publication on August 6, 2015 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and
systems for assessing and preserving organs outside the body and for selecting
usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the
USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker
symbol XVIVO. More information can be found on the website
www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity
number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com